REGN Regeneron Pharmaceuticals Inc.

Regeneron Announces Investor Conference Presentations

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

  • Oppenheimer 34th Annual Healthcare Life Sciences Conference at 1:20 p.m. ET on Wednesday, February 14, 2024



  • TD Cowen 44th Annual Health Care Conference at 11:10 a.m. ET on Wednesday, March 6, 2024



  • Barclays 26th Annual Global Healthcare Conference at 11:15 a.m. ET on Tuesday, March 12, 2024



  • Leerink Partners Global Biopharma Conference 2024 at 10:40 a.m. ET on Wednesday, March 13, 2024

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at . Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.

About Regeneron

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for over 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.

Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. 

Regeneron is accelerating and improving the traditional drug development process through its proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world. 

For additional information about Regeneron, please visit  or follow Regeneron on .

Contact Information:

Investor Relations

Ryan Crowe

914.847.8790

        



EN
06/02/2024

Underlying

REGNRegeneron Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Regeneron Pharmaceuticals Inc.

 PRESS RELEASE
Free
REGN Regeneron Pharm...

Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Lev...

Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks Preliminary data detailed in an ASGCT oral presentation include results for one of the youngest children in the world to receive a gene therapy for genetic deafness Ongoing Phase 1/2 CHORD trial is currently enrolling infants and children in the U.S., UK and Spain TARRYTOWN, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the investigatio...

May 8, 2024 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron Announces Investor Conference Presentations

Regeneron Announces Investor Conference Presentations TARRYTOWN, N.Y., May 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: RBC Capital Markets Global Healthcare Conference at 9:00 a.m. ET on Tuesday, May 14, 2024Jefferies Global Healthcare Conference at 8:30 a.m. ET on Wednesday, June 5, 2024Goldman Sachs 45th Annual Global Healthcare Conference at 8:00 a.m. ET on Tuesday, June 11, 2024 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at . Replays and transcripts of the web...

May 6, 2024 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron Reports First Quarter 2024 Financial and Operating Results

Regeneron Reports First Quarter 2024 Financial and Operating Results First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HDFirst quarter 2024 Libtayo® global net sales increased 45% to $264 million versus first quarter 2023First quarter 2024 GAAP diluted EPS of $6.27 and non-GA...

May 2, 2024 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce...

EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases Long-term data and subgroup analyses from pivotal EYLEA HD clinical program continue to demonstrate durable efficacy and consistent safety in patients with wet age-related macular degeneration and certain diabetic eye diseases TARRYTOWN, N.Y., April 29, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of positive long-term results and subgroup analyses from the pivotal clinical program of E...

April 29, 2024 1 EN
 PRESS RELEASE
Free
REGN Regeneron Pharm...

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generatio...

Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases Mammoth’s proprietary ultracompact CRISPR-based gene editing platform and Regeneron’s proprietary delivery technologies set to advance in vivo programs in multiple tissue and cell types Mammoth to receive $100 million total upfront payment and equity investment from Regeneron at signing TARRYTOWN, N.Y., April 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Mammoth Biosciences, Inc., today announced a collaboration to research, develop and...

April 25, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch